Please assess the completion status of the following clinical trial:

Trial Title: Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with thalassemia major with at least 6 years of age undergoing iron chelation therapy.~2. No anticipated changes in chelation regimen for the next 12 months~3. Completed and signed Informed Consent~Exclusion Criteria:~1. Pregnancy~2. Advanced class III/IV heart failure or LVEF \< 0.35% (by MRI)~3. Formal contra-indications to MRI (pacemakers, cerebral aneurysm metal clips, etc).~4. Advanced heart AV block

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Starch pill (Type: PLACEBO_COMPARATOR): Placebo
- Amlodipine (Type: EXPERIMENTAL): Amlodipine 5mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).